Blue Matter Blog
October 31, 2022
As highlighted in our previous blog post, the Netherlands Cancer Institute (NKI) demonstrated compelling efficacy data from the first randomized, controlled Phase 3 study comparing tumor-infiltrating lymphocytes (TILs) to a checkpoint immunotherapy (Yervoy®) in advanced melanoma. Earlier this year, Iovance Biotherapeutics announced positive clinical data for its TIL (lifileucel), also in advanced melanoma. TIL therapy …
October 17, 2022
In our previous installment, we explored the fact that therapy with a psychedelic substance typically goes far beyond the medicine itself. Most often, it’s integrated with preparatory counseling, therapist support during the drug treatment itself, and talk therapy after a drug treatment. This, of course, can have significant implications for the overall cost of therapy, …
October 7, 2022
In Part I of this series, we discussed the surging levels of interest and investment in psychedelic therapies. After decades of lying dormant, psychedelic medicines are back, and a lot of research dollars are being invested to bring them to market. However, there is more to psychedelic therapy than the drugs themselves. Many psychedelics being …
October 5, 2022
The European Society for Medical Oncology (ESMO) held its annual congress in Paris last month, September 9-13. The conference provided a venue for multiple presentations in the cell therapy space. These presentations showcased data on the efficacy of cell therapies—mostly in solid tumors—leveraging multiple innovations, including a variety of cell types such as tumor infiltrating …
October 4, 2022
Interest in psychedelic therapy has risen substantially in recent years, and it’s easy to see why. After decades of being ignored due to legislative action, psychedelic substances now represent an emerging class with the potential to be disease modifying across a range of mental and behavioral health issues. We’ve written about psychedelics before, and that …